Valuation: Aquestive Therapeutics, Inc.

Market Cap 473M 416M 386M 355M 667M 45.81B 679M 4.62B 1.8B 22.34B 1.78B 1.74B 77.51B P/E 2026 *
-9.31x
P/E 2027 * -9.71x
Enterprise Value 388M 341M 317M 292M 547M 37.58B 557M 3.79B 1.48B 18.33B 1.46B 1.43B 63.58B EV / Sales 2026 *
7.68x
EV / Sales 2027 * 6.58x
Free-Float
96.94%
Yield 2026 *
-
Yield 2027 * -
1 day-4.31%
1 week-4.31%
Current month-9.38%
1 month-25.05%
3 months-7.37%
6 months+16.36%
Current year-41.64%
1 week 3.76
Extreme 3.76
4.18
1 month 3.76
Extreme 3.76
4.9
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap.
16/7/26 Sell

Chief Executive Officer

-20,369 0.0162%
23/6/26 Fiscal year

Director

75,000 0.0598%
15/6/26 Sell

Chief Executive Officer

-25,000 0.0199%
Change 5-day change 1-year change 3-year change Capi.($)
-4.31%-4.31%-11.50%+138.61% 494M
+1.97%+1.43%+48.44%+156.66% 1,037B
+1.42%+3.72%+53.32%+52.34% 615B
+1.43%+0.99%+34.83%+78.74% 448B
+5.14%+5.40%+33.75%+27.28% 326B
+1.85%+3.57%+37.09%+39.87% 293B
-0.11%+0.48%+18.87%+17.81% 264B
+0.25%-4.62%-27.66%-42.25% 216B
+1.49%-0.02%+20.14%+58.21% 198B
+0.40%-3.99%+15.23%+62.28% 162B
Average +0.95%-0.16%+22.25%+58.95% 355.79B
Weighted average by Cap. +1.73%+1.12%+35.40%+75.24%

Financials

2026 *2027 *
Net sales 50.51M 44.43M 41.27M 37.96M 71.18M 4.89B 72.46M 494M 192M 2.39B 190M 186M 8.28B 71.92M 63.25M 58.76M 54.04M 101M 6.96B 103M 703M 274M 3.4B 270M 264M 11.79B
Net income -50.65M -44.54M -41.38M -38.06M -71.37M -4.9B -72.65M -495M -193M -2.39B -190M -186M -8.3B -47.99M -42.21M -39.21M -36.07M -67.64M -4.65B -68.85M -469M -183M -2.27B -180M -176M -7.86B
Net Debt -85M -74.76M -69.45M -63.87M -120M -8.23B -122M -830M -324M -4.01B -319M -312M -13.93B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
23/07/26 USD 3.770 -4.31% 2,015,742
22/07/26 USD 3.940 -2.48% 1,707,558
21/07/26 USD 4.040 +2.41% 1,797,137
20/07/26 USD 3.945 -4.25% 1,434,370
17/07/26 USD 4.120 +4.57% 2,356,421
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.770USD
Average target price
8.889USD
Spread / Average Target
+135.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock